EUS-guided ablation for pancreatic cystic lesions: An updated review.

Pancreatic cystic lesions (PCLs) are a globally prevalent condition, with incidence increasing with age. The proper treatment modality for PCLs remains a controversial topic. EUS-guided ablation represents an innovative and promising minimally invasive treatment for selected PCL patients, including EUS-guided pancreatic cyst chemoablation (EUS-PCC, such as ethanol, lauromacrogol, chemotherapeutic agents, and combination therapies) and EUS-guided radiofrequency ablation (EUS-RFA). Each treatment modality varies in treatment indications, efficacy, and safety. Herein, with ongoing advancements in clinical research, we present a comprehensive, updated review of procedural techniques, patient selection, clinical outcomes, and adverse events for EUS-PCC and EUS-RFA.